Among these, HAO1, SCL27A2, DAO, ABAT, and PCK2, rarely reported in HCC to date, were validated as novel hub genes that may serve as effective clinical diagnostic and prognostic markers as well as therapeutic targets for HCC. The gene discussed is PCK2; the disease is hepatocellular carcinoma.